Pierre d’Epenoux, ImCheck CEO
September 15, 2020 07:18 AM EDT
Financing

Im­Check adds $7.1M to Se­ries B, boost­ing de­vel­op­ment of gam­ma delta T cell pro­grams

Max Gelman

Senior Editor

Nine months af­ter first an­nounc­ing a Se­ries B, French biotech Im­Check re­turned to the ven­ture cap­i­tal well seek­ing a bit more cash.

The com­pa­ny found …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times